Prior-Cancer Diagnosis in Men with Nonmetastatic Prostate Cancer and the Risk of Prostate-Cancer-Specific and All-Cause Mortality

Table 1

Comparison of the distribution of clinical characteristics of the 166,104 men stratified by a history of cancer prior to the PC diagnosis versus no prior cancer.

Clinical characteristics	Number (%) of men without a prior cancer	Number (%) of men with a prior cancer	𝑃 value
	𝑁=164,647	𝑁=1,457
Race
African American	20208 (12.3%)	108 (7.4%)	<0.001
Other	144439 (87.7%)	1349 (92.6%)
Year of diagnosis (range)
2004	39609 (24.1%)	392 (26.9%)	0.035
2005	37072 (22.5%)	335 (23.0%)
2006	42810 (26.0%)	366 (25.1%)
2007	45156 (27.4%)	364 (25.0%)
Age at diagnosis
Median (IQR) (yr)	66 (60, 73)	72 (66, 78)	0.001
<50 yr	5206 (3.2%)	9 (0.6%)	<0.001
50–59 yr	35570 (21.6%)	115 (7.9%)
60–69 yr	62463 (37.9%)	437 (30.0%)
≥70 yr	61408 (37.3%)	896 (61.5%)
Gleason score
≤6	77736 (47.2%)	649 (44.5%)	<0.001
7	62016 (37.7%)	529 (36.3%)
8 to 10	24895 (15.1%)	279 (19.2%)
Clinical tumor stage
1c	61793 (37.5%)	612 (42.0%)	<0.001
2a–2c	87327 (53.0%)	737 (50.6%)
3-4	15527 (9.4%)	108 (7.4%)
PSA
Median (IQR)	6.5 (4.7, 10.6)	7.0 (4.7, 12.3)	0.59
≤4.0 ng/mL	23839 (14.5%)	230 (15.8%)	<0.001
>4.0–10.0 ng/mL	96632 (58.7%)	746 (51.2%)
10.1–20.0 ng/mL	25360 (15.4%)	297 (20.4%)
>20.0 ng/mL	18816 (11.4%)	184 (12.6%)
Risk group
Low risk	28682 (17.4%)	240 (16.5%)	0.01
Intermediate risk	91819 (55.8%)	778 (53.4%)
High risk	44146 (26.8%)	439 (30.1%)
Treatment approach
Curative	123674 (75.1%)	954 (65.5%)	<0.001
Other Rx	4017 (2.4%)	59 (4.1%)
Watchful-waiting/active surveillance	36956 (22.5%)	444 (30.5%)
Median followup (IQR) (years)	2.75 (1.85, 3.92)	3.0 (2.0, 4.17)	<0.001

CI: confidence interval. Dx: diagnosis. IQR: interquartile range. PC: prostate cancer. Yr: year.